That headline is too vague to be safe—the specific tablet matters. Some medicines really do carry warnings about blood clots or cardiovascular events, but many others do not.
For example, the FDA has warned about increased risks of blood clots, heart attack, stroke, and death with certain JAK-inhibitor medicines, including tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq), particularly in people with cardiovascular risk factors. U.S. Food and Drug Administration+1
Other medicines can have completely different risk profiles. In fact, some tablets prevent blood clots and strokes; stopping them suddenly can increase clotting risk. For example, stopping rivaroxaban (Xarelto) without medical guidance can increase the risk of a blood clot and stroke. FDA Access Data
Don’t stop any prescribed tablet because of this headline. If you give me the name of the tablet (or a photo of the package), I can explain exactly whether it is associated with blood clots, heart attack, or stroke and who is most at risk.
